--- title: "RFG Advisory LLC Acquires New Holdings in Avadel Pharmaceuticals PLC. $AVDL" type: "News" locale: "en" url: "https://longbridge.com/en/news/275748502.md" description: "RFG Advisory LLC has acquired a new position in Avadel Pharmaceuticals PLC, purchasing 73,944 shares valued at approximately $1.13 million. This acquisition represents about 0.08% of the company. Other hedge funds have also increased their stakes in Avadel, with significant purchases from Brandes Investment Partners, Two Seas Capital, and Geode Capital Management. Avadel Pharmaceuticals, focused on treatments for rare diseases, has seen its stock rated as 'Hold' by several analysts, with a consensus target price of $20.00." datetime: "2026-02-12T11:38:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275748502.md) - [en](https://longbridge.com/en/news/275748502.md) - [zh-HK](https://longbridge.com/zh-HK/news/275748502.md) generator: "portal-rs" --- # RFG Advisory LLC Acquires New Holdings in Avadel Pharmaceuticals PLC. $AVDL RFG Advisory LLC acquired a new position in Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 73,944 shares of the company's stock, valued at approximately $1,129,000. RFG Advisory LLC owned approximately 0.08% of Avadel Pharmaceuticals as of its most recent SEC filing. - There May Still Be Time to Get in on These 3 Trending Biotechs Other hedge funds also recently bought and sold shares of the company. Brandes Investment Partners LP increased its holdings in shares of Avadel Pharmaceuticals by 14.5% in the 2nd quarter. Brandes Investment Partners LP now owns 6,487,642 shares of the company's stock valued at $57,416,000 after acquiring an additional 820,467 shares during the period. Two Seas Capital LP grew its stake in Avadel Pharmaceuticals by 24.4% in the second quarter. Two Seas Capital LP now owns 6,155,074 shares of the company's stock valued at $54,472,000 after purchasing an additional 1,208,625 shares during the last quarter. Geode Capital Management LLC raised its holdings in Avadel Pharmaceuticals by 82.3% in the second quarter. Geode Capital Management LLC now owns 2,169,018 shares of the company's stock worth $19,198,000 after purchasing an additional 979,422 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of Avadel Pharmaceuticals by 30.1% during the second quarter. Kennedy Capital Management LLC now owns 981,271 shares of the company's stock valued at $8,684,000 after buying an additional 227,228 shares during the last quarter. Finally, Krensavage Asset Management LLC boosted its holdings in shares of Avadel Pharmaceuticals by 0.9% in the 2nd quarter. Krensavage Asset Management LLC now owns 958,877 shares of the company's stock valued at $8,486,000 after buying an additional 8,877 shares in the last quarter. Hedge funds and other institutional investors own 69.19% of the company's stock. Get **Avadel Pharmaceuticals** alerts: ## Avadel Pharmaceuticals Price Performance Shares of AVDL opened at $21.64 on Thursday. The company's fifty day moving average price is $21.51 and its 200-day moving average price is $18.17. Avadel Pharmaceuticals PLC. has a 1-year low of $6.38 and a 1-year high of $23.57. ## Analysts Set New Price Targets Several research firms recently commented on AVDL. UBS Group lowered shares of Avadel Pharmaceuticals to a "neutral" rating in a research note on Tuesday, October 28th. Piper Sandler downgraded Avadel Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 22nd. HC Wainwright cut Avadel Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $20.00 price objective for the company. in a research report on Thursday, October 23rd. Needham & Company LLC lowered Avadel Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday, October 22nd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Avadel Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $20.00. **View Our Latest Analysis on AVDL** ## Avadel Pharmaceuticals Company Profile (Free Report) Avadel Pharmaceuticals plc is a global specialty biopharmaceutical company focused on developing and delivering treatments for rare diseases and central nervous system disorders. Headquartered in Dublin, Ireland, with operations in the United States, Avadel's portfolio centers on sleep disorder therapeutics, including its flagship low-sodium oxybate product, XYWAV, which is approved in the U.S. for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. The company is also advancing FT218, a once-nightly formulation of sodium oxybate, currently under regulatory review for narcolepsy management. Formed through a rebranding of Flamel Technologies in 2016 and a strategic shift toward rare disease drug development, Avadel has built its R&D capabilities around improving patient compliance and reducing daily sodium exposure compared to traditional therapies. ## Featured Stories - Five stocks we like better than Avadel Pharmaceuticals - Is THIS the Next Big Money Rush? - Wall Street Legend Names #1 Stock of 2026 Live On-Camera - ISPC: From Small Cap to Life Sciences Market Disruptor! - The Crash Has Already Started (Most Just Don’t See It Yet) - INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Avadel Pharmaceuticals Right Now? Before you consider Avadel Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avadel Pharmaceuticals wasn't on the list. While Avadel Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [AVDL.US](https://longbridge.com/en/quote/AVDL.US.md) ## Related News & Research - [Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears](https://longbridge.com/en/news/289363475.md) - [Alkermes reports Q2 2026 revenue $496.0M, GAAP net income $0.5M, Adjusted EBITDA $139.2M](https://longbridge.com/en/news/294056109.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**